Hannah L Nathan

Dr. Hannah L Nathan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XYXi Yang
Xi Yang
HNHannah L Nathan
Hannah L Nathan
EOEbruba Ese Oyekan
Ebruba Ese Oyekan
TKTim I. M. Korevaar
Tim I. M. Korevaar
DADoaa Ibrahim Mohamed Ahmed
Doaa Ibrahim Mohamed Ahmed
COCaroline Ovadia
Caroline Ovadia
Objectives: We aimed to develop and validate a simple, easy-to-use risk stratification tool to use in the diagnosis of gestational diabetes mellitus (GDM) to triage those more likely to require insulin treatment. Methods: Using an audit of patients with GDM in 2019, multivariable logistic regression was used to select variables and develop a prediction model for insulin requirement. A stratification tool was developed by dichotomising these selected variables; its performance was assessed with an internal cohort from 2021 and externally from patients managed at a separate hospital. Results: Patients with a higher fasting blood glucose concentration (OR 2.41, 95% CI 1.84–3.15) and higher booking body mass index (OR 1.48, 95% CI 1.07–2.03) were more likely to require insulin therapy whilst a later gestational-weeks-at-diagnosis value gave a lower risk of insulin therapy (OR 0.71, 95% CI 0.62–0.81 per week). The low-risk group for insulin requirement was defined thus: fasting blood glucose < 5.6 mmol/L, booking BMI < 30 kg/m2, and gestational weeks at diagnosis ≥ 24 weeks. This classification had a negative predictive value (NPV) of 94% for insulin requirement, with a sensitivity of 84% and specificity of 56% in the development cohort. Similarly, in the internal and external validation cohorts, the NPVs were 93 and 90%, with sensitivity values of 77 and 78%, respectively. Conclusions: This study developed a pragmatic tool with three criteria for stratifying the GDM group not requiring insulin treatment, with successful validation for clinical use.

31 May 2025 in Journal of Case Reports and Images in Oncology
Verified
Journal Article
Open access
PDF file
HGHannah Gerretsen
Hannah Gerretsen
MNMelanie Nana
Melanie Nana
HNHannah L Nathan
Hannah L Nathan
CNCatherine Nelson-Piercy
Catherine Nelson-Piercy
SGSpyridon Gennatas
Spyridon Gennatas
Introduction: Cancer diagnosis during pregnancy is rare, but the incidence is expected to rise. Lung cancer during pregnancy is often diagnosed at an advanced stage, with overall poor prognosis. Symptoms are often attributed to alternative diagnoses or physiological changes of pregnancy. Diagnostic imaging is also sometimes delayed due to concerns regarding the hazardous effects of radiation exposure on the fetus. Case Series: We present two cases of patients diagnosed with metastatic lung adenocarcinoma during pregnancy. Neither patient had a targetable mutation for treatment, but were found to have KRAS G12D-mutation. Both patients were started on carboplatin, pemetrexed, and pembrolizumab after delivery of their babies. They both died a few months post-diagnosis. Conclusion: Evidence regarding management of lung cancer in pregnancy is limited, based on case reports and no randomized control trials. This case series highlights the importance of clinicians having a low threshold to investigate for cancer in pregnancy, to aid earlier diagnosis and improve prognosis.